Zoetis Plunges 21.5% on Guidance Cut; Securities Fraud Investigation Launched

What happened

Zoetis slashed its full-year 2026 revenue outlook after reporting disappointing Q1 results on May 7, triggering a 21.5% single-day stock decline and erasing roughly $23.91 per share in value. The guidance cut underscores persistent headwinds in the osteoarthritis monoclonal antibody franchise, which the DeepValue master report had flagged as a key risk, and adds to concerns about slowing companion-animal growth and livestock softness. Following the rout, Levi & Korsinsky announced a securities fraud investigation, alleging potential misrepresentations about Zoetis's business prospects, though the firm's track record of filing such investigations after large drops warrants skepticism. The market is now pricing in a structural slowdown rather than a temporary blip, with the stock trading near the low end of the bear-case scenario outlined in the master report ($100 implied value). Zoetis's core franchises remain strong, but the combination of deteriorating fundamentals and legal overhang creates an unfavorable risk-reward near term.

Implication

The guidance cut and fraud probe validate the bear-case thesis that OA mAbs and growth are structurally impaired. A re-rating toward high-teens P/E is likely if organic growth stays below 5%, making $100 a realistic floor. Patience required until OA stabilization or a deep discount emerges.

Thesis delta

The bear-case scenario has become the base case: guidance cuts confirm OA franchise weakness and slowing growth, raising the probability of below-5% organic growth and multiple compression. The securities investigation adds noise but does not change the fundamental deterioration. Our WAIT rating shifts to cautious underweight; only a price near $100 or clear evidence of OA recovery would warrant re-entry.